Navigation Links
Nasal Anthrax Vaccine Proves Effective in Animal Study
Date:8/31/2007

Though not ready for humans, it offered immunity for at least 6 months

FRIDAY, Aug. 31 (HealthDay News) -- An experimental nasal anthrax vaccine proved highly effective in tests in mice and guinea pigs, a University of Michigan Medical School study shows.

After it was placed inside the animals' noses, the vaccine triggered a strong immune response. All immunized guinea pigs survived after they received injections of 1,000 times the lethal dose of anthrax spores. All unprotected guinea pigs died.

From 40 percent to 70 percent of immunized animals survived after large doses of anthrax spores were placed directly in their nasal tissue.

In these animal experiments, there have been no significant side effects, and the vaccine has produced effective immunity for at least six months, the study said.

The nasal vaccine features tiny soybean oil droplets that are small enough to carry an anthrax protein inside the nasal membrane. Immune system cells then react to the anthrax protein and prime the entire immune system to attack anthrax.

This nasal vaccine is easier and more effective than the current injectable vaccine, according to the researchers. The nasal vaccine is also easier to store and use in locations where there is no available refrigeration.

The next step is to test whether the vaccine produces immunity in primates. The researchers are also preparing plans for safety studies in humans.

The study was published in the August issue of Infection and Immunity.

More information

The U.S. Centers for Disease Control and Prevention has more about anthrax.



-- Robert Preidt



SOURCE: University of Michigan Health System, news release, August 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Nasal Spray Could Take Drugs Direct to Brain.
2. Nasal Spray Could Take Drugs Directly to Brain
3. Nasal Spray Beats Antihistamine
4. Nasal sprays used for other ailments!
5. Chronic Sinusitis May Be Related To Nasal Mucus
6. Stress – Buster : Hormonal Nasal Spra
7. CDC To Conduct Pre-clinical Trails Of BioDiems Intranasal Bird Flu Vaccine
8. Cluster Headaches Can Be Treated By Nasal Spray
9. Nasal Plastic Surgery Improves Airway Function
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. Patients Dissatisfied Following Closed Reduction Of Nasal Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... Patient warming and ... blood during surgeries, lowering the risks of neurological disorders post ... SSIs. The patient warming systems can be segmented into convective ... in turn reduce the stay at hospitals thus, lowering the ...
Breaking Medicine Technology: